Russian astronomers fail to detect meteorite’s crash in SiberiaScience & Space December 07, 11:40
Russia’s Almaz-Antey to modernize Iran’s aircraft navigation systemMilitary & Defense December 07, 11:06
Russian colonel killed by 'opposition' shelling in AleppoMilitary & Defense December 07, 10:56
Mission Control Center reveals cause of Progress spacecraft lossScience & Space December 07, 10:44
The Range: The Caucasus from sea to seaSociety & Culture December 07, 10:27
OPEC, Russia agree on mutually accepted formula of oil production cut for 6 monthsBusiness & Economy December 07, 9:59
Maduro to oversee implementation of agreements on cooperation with Russia 'personally'Business & Economy December 07, 9:10
Washington says will negotiate with Moscow on Syria only 'if talks are constructive'World December 07, 8:35
'Harry Potter and the Cursed Child' hits store shelves in RussiaSociety & Culture December 07, 8:12
SAN FRANCISCO, Dec. 7, 2015 /PRNewswire/. Medicines360, a global nonprofit pharmaceutical company, today announced an agreement with Marie Stopes International (MSI), a global nonprofit family planning organization, to expand access to Medicines360's hormonal intrauterine device, LNG IUS (levonorgestrel-releasing intrauterine system, 52mg), bringing further contraceptive options to the women of Kenya.
Logo - http://photos.prnewswire.com/prnh/20151203/293047LOGO
Logo - http://photos.prnewswire.com/prnh/20151203/293150LOGO
Kenya is the first country outside of the U.S. in which Medicines360 plans to launch its 52mg hormonal interuterine device (IUD). A hormonal IUD is among the most efficacious forms of contraception and Medicines360 plans to make their LNG IUS available to women in other countries that have a high unmet need for contraception.
"This partnership with MSI marks our first effort in Africa and will help us achieve our mission of expanding access to quality medicines to women, and positively impacting women's lives around the globe," said by Dr. Jessica Grossman, CEO of Medicines360. "Our collaboration with MSI will help women in Kenya access an affordable, high quality hormonal contraceptive method in places where hormonal IUDs have not been readily available or distributed."
"When a woman has access to contraception, she is able to make choices about her own future, and that of her family," said Helen Blackholly, Marie Stopes International. "We work every day in our country programs to ensure that more women than ever before are able to access contraception. However, particularly in sub-Saharan Africa, the need is greater than current efforts. We are delighted that this new partnership with Medicines360 will help more women, in some of the most underserved communities in the world, meet their family planning needs."
Medicines360, located in San Francisco, California, is an innovative nonprofit global women's health pharmaceutical company with a mission to expand access to quality medicines for all women regardless of their socioeconomic status, insurance coverage or geographic location. Medicines360 is committed to working with healthcare providers, advocacy groups and patients to deliver innovative and meaningful treatments that help women around the world have greater access to the medicines they need. For more information, visit www.medicines360.org
About Marie Stopes International
Marie Stopes International is a global organisation providing personalised contraception and safe abortion services to women and girls. Our local teams of professionals are passionate about the work they do in communities across 37 countries.
The high quality services we provide give a woman the power to choose when she has children so that she's free to pursue her plans and dreams for herself and her family. For more information, visit www.mariestopes.org